LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In American Renal Associates Holdings, Inc. To Contact The Firm

    0
    337
    Reading Time: 3 minutes

    NEW YORK–(BUSINESS WIRE)–Faruqi & Faruqi, LLP, a leading national securities law firm, reminds
    investors in American Renal Associates Holdings, Inc. (“American Renal”
    or the “Company”)(NYSE:ARA) of the May 28, 2019 deadline to seek the
    role of lead plaintiff in a federal securities class action that has
    been filed against the Company.

    If you invested in American Renal stock or options between August 10,
    2016 and March 27, 2019
    and would like to discuss your legal rights, click
    here:
    www.faruqilaw.com/ARA.
    There is no cost or obligation to you.

    You can also contact us by calling Richard Gonnello toll free at 877-247-4292
    or at 212-983-9330 or by sending an e-mail to [email protected].

    The lawsuit has been filed in the U.S. District Court for the District
    of New Jersey on behalf of all those who purchased American Renal
    securities between August 10, 2016 and March 27, 2019 (the “Class
    Period”). The case, Vandevar v. American Renal Associates
    Holdings, Inc.
    , No. 19-cv-09074 was filed on March 28, 2019.

    The lawsuit focuses on whether the Company and its executives violated
    federal securities laws by failing to disclose that: (1) issues with
    American Renal’s accounting process for revenue recognition,
    collections, and related matters would give rise to an SEC investigation
    into the same, and increased regulatory scrutiny by the SEC; (2)
    American Renal’s financial statements for the fiscal years 2014, 2015,
    2016 and 2017 contained in its Annual Reports for the years ended
    December 31, 2016 and 2017, and its condensed consolidated financial
    statements in quarterly reports from 2016 through 2018 were false and
    could not be relied upon; (3) American Renal had material weaknesses in
    its internal control over financial reporting; and (4) as a result,
    American Renal’s public statements were materially false and misleading
    at all relevant times.

    On November 9, 2018, American Renal filed a Form 10-Q with the SEC in
    which the Company disclosed that in October 2018, SEC staff “requested
    that the Company voluntarily provide documents and information relating
    to certain revenue recognition, collections and related matters.”

    On this news, American Renal’s share price fell from $17.50 per share on
    November 9, 2018 to a closing price of $16.76 on November 12, 2018: a
    $0.74 or a 4.23% drop.

    On March 8, 2019, before the market opened, American Renal filed a Form
    NT 10- K with the SEC, announcing it would delay the filing of its
    earnings report for the fiscal year ended December 31, 2018 as it
    continues to examine reserve computations and other accounting practices
    that may have an impact on the company’s accounts receivable and revenue
    for 2018, as well as previously reported fiscal years ranging from 2014
    through 2017.

    On this news, American Renal’s share price fell from $12.51 per share on
    March 7, 2019 to a closing price of $10.46 on March 8, 2019: a $2.05 or
    a 16.39% drop.

    Then, on March 27, 2019, after market hours, American Renal announced
    the resignation of its CFO, and that American Renal would restate its
    financial results for the fiscal years ended 2014 through 2017.

    On this news, American Renal’s share price fell from $9.70 per share on
    March 27, 2019 to a closing price of $6.01 on March 28, 2019: a $3.69 or
    a 38.04% drop.

    The court-appointed lead plaintiff is the investor with the largest
    financial interest in the relief sought by the class who is adequate and
    typical of class members who directs and oversees the litigation on
    behalf of the putative class. Any member of the putative class may move
    the Court to serve as lead plaintiff through counsel of their choice, or
    may choose to do nothing and remain an absent class member. Your ability
    to share in any recovery is not affected by the decision to serve as a
    lead plaintiff or not.

    Faruqi & Faruqi, LLP also encourages anyone with information regarding
    American Renal’s conduct to contact the firm, including whistleblowers,
    former employees, shareholders and others.

    Attorney Advertising. The law firm responsible for this advertisement is
    Faruqi & Faruqi, LLP (www.faruqilaw.com).
    Prior results do not guarantee or predict a similar outcome with respect
    to any future matter. We welcome the opportunity to discuss your
    particular case. All communications will be treated in a confidential
    manner.

    Contacts

    FARUQI & FARUQI, LLP
    685 Third Avenue, 26th Floor
    New
    York, NY 10017
    Attn: Richard Gonnello, Esq.
    [email protected]
    Telephone:
    (877) 247-4292 or (212) 983-9330